The Effects of Carbamylation on HBA1C in Chronic Renal Failure Patient
Author(s): P Ravisekar and B Shanthi*
Abstract
Chronic renal failure occurs, when disease or disorders damages the kidneys so that they are no longer capable of adequately removing fluids and wastes from the body or of maintaining the proper level of certain kidney - regulated chemicals in the blood stream. It is caused by several diseases and inherited disorders, but the progression of chronic kidney failure is always the same. The kidneys, which serve as the body's natural filtration system, gradually lose their ability to remove fluids and waste products (urea) from the bloodstream. They also fail to regulate certain chemicals in the bloodstream, and deposit protein into the urine. Chronic kidney failure is irreversible, and will eventually lead to total kidney failure, also known as end stage renal disease (ESRD). Without proper treatment intervention to remove wastes and fluids from the bloodstream, ESRD is fatal. Glycated hemoglobin (hemoglobin A1c, HbA1c, A1C, or Hb1c) is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. This serves as a marker for average blood glucose levels over the previous 3 months prior to the measurement as this is the half-life of red blood cells. Our present study based on the estimation of HbA1c level in diabetic patients with and without chronic kidney diseases (CKD) and HbA1C on serial monitoring can be marker for assessing renal disease.